PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Luis Paz-Ares
Consultant or Advisory Role - Bayer; Lilly; Pfizer; Roche
Honoraria - Bayer; Lilly; Pfizer; Roche
Filippo De Marinis
No relevant relationships to disclose
Mircea Dediu
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Michael Thomas
Consultant or Advisory Role - AstraZeneca
Honoraria - Speaker's Honoraria
Research Funding - AstraZeneca
Jean-Louis Pujol
Consultant or Advisory Role - Lilly
Paolo Bidoli
No relevant relationships to disclose
Oliver Molinier
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Tarini Prasad Sahoo
No relevant relationships to disclose
Eckart Laack
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Roche
Jesus Corral Jaime
No relevant relationships to disclose
Symantha Melemed
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
William J. John
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Nadia Chouaki
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Annamaria Zimmermann
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Carla Visseren-Grul
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Cesare Gridelli
Consultant or Advisory Role - Lilly
Honoraria - Lilly